Direct Flow Medical
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $8.4m | Series A | |
$27.0m | Series B | ||
$40.0m | Series C | ||
$280k | Seed | ||
$50.0m | Debt | ||
N/A | Debt | ||
$31.0m | Series C | ||
N/A | $27.1m | Series A | |
Total Funding | €122m |
Recent News about Direct Flow Medical
EditDirect Flow Medical specializes in providing effective solutions for erectile dysfunction and benign prostatic hyperplasia through its flagship product, Tadalafil, sold under the brand name Cialis. The company operates in the pharmaceutical market, targeting adult men who experience these medical conditions. Direct Flow Medical's business model revolves around the sale of both branded and generic versions of Cialis, offering various dosages to meet different patient needs. Revenue is generated through direct sales to consumers via their online platform, as well as through partnerships with healthcare providers and pharmacies. The company emphasizes the long-lasting effects of its product, which can last up to 36 hours, and its ability to work independently of food intake, setting it apart from many other erectile dysfunction drugs.
Keywords: erectile dysfunction, benign prostatic hyperplasia, Tadalafil, Cialis, pharmaceutical, long-lasting, online sales, healthcare partnerships, adult men, smooth muscle relaxation.